<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45283">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01982526</url>
  </required_header>
  <id_info>
    <org_study_id>2011-84</org_study_id>
    <nct_id>NCT01982526</nct_id>
  </id_info>
  <brief_title>Role of Anti Mullerian Hormone for Ovarian Reserve Determination of Preoperative and Postoperative Endometrioma Patients</brief_title>
  <official_title>Role of Anti Mullerian Hormone for Ovarian Reserve Determination of Preoperative and Postoperative Endometrioma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanuni Sultan Suleyman Training and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kanuni Sultan Suleyman Training and Research</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ovarian reserve influenced by many factor but especially cysts like endometrioma. Anti
      mullerian hormone is recent marker for ovarian reserve. The investigators are searching
      ovarian reserve pre and post operatively by using antimullerian hormone of endometrioma
      patient who are operated for their cysts.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Long term postoperative ovarian reserve outcomes of endometrioma patients by examining antimullerian hormone.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Endometrioma</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Endmetrioma surgery</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We are collecting serum samples of pre and post operative endometroma patients and measuring
      anti m√ºllerian hormone levels.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Females who are administring gynecology clinic suffering from symptomatic benign ovarian
        cysts.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ultrasonographical symptomatic and benign cysts which has surgery indication.

        Exclusion Criteria:

          -  Over 42 years old, systemic endocrine disorder, history of ovarian surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ergul Demircivi Bor, MD</last_name>
    <phone>+902124041500</phone>
    <phone_ext>1683</phone_ext>
    <email>drergul@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kanuni Sultan Suleyman Education and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>November 12, 2013</lastchanged_date>
  <firstreceived_date>November 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kanuni Sultan Suleyman Training and Research</investigator_affiliation>
    <investigator_full_name>Ergul Demircivi Bor</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Ovarian reserve</keyword>
  <keyword>Antimullerian hormone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
